Post-earnings recap
Reported
Thu, Feb 26, 2026
EPS actual
$2.02
EPS est.
$0.63
EPS surprise
+219.62%
1-day move
+2.50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ligand Pharmaceuticals reported a strong earnings per share figure, significantly exceeding expectations, which contributed to a 2.5% increase in stock price. The lack of revenue data and guidance may leave investors with questions about future performance. Overall, the positive EPS surprise indicates strong management of costs or successful product launches.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.02 | N/A | +219.62% |
| Revenue | N/A | N/A | N/A |
Management highlighted the strong EPS results as a positive sign for the company. However, they did not provide specific revenue guidance for the future.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They emphasized ongoing efforts to enhance operational efficiency.